key: cord-0969031-k5k1eeev
authors: Chung, James J.; Rayburn, Maire C.; Chigerwe, Munashe
title: Randomized controlled clinical trial on the effect of oral immunoglobulin supplementation on neonatal dairy calves with diarrhea
date: 2019-05-24
journal: J Vet Intern Med
DOI: 10.1111/jvim.15538
sha: 29ead3f1e4f24c9158b65d37a4ba9d839fb9028c
doc_id: 969031
cord_uid: k5k1eeev

BACKGROUND: Nonantibiotic alternatives providing local gut immunity have been recommended for managing calf diarrhea. ANIMALS: One hundred and two calves with diarrhea. HYPOTHESIS: Oral supplementation with immunoglobulins in calves with diarrhea will reduce time to resolution of diarrhea, number of treatment events, and mortality rate. METHODS: Randomized controlled trial. Calves were assigned into 1 of 3 groups. The treatment group was supplemented with 20 g of immunoglobulins in milk twice daily for 14 days. The placebo group was supplemented with 20 g of a product with similar nutritional value as the treatment group, but without immunoglobulins, in milk, twice daily for 14 days. The control group received no supplements. Medical treatments, time to resolution of diarrhea, and case fatality rates were compared. RESULTS: There was no difference in the proportion of treatment events (treatment, 79% versus placebo, 77% versus control, 71%) among groups (P = .69). The median time to resolution of diarrhea was not different between the treatment (10.5 days; 95% confidence interval [CI], 7, 13) and control (8 days; 95% CI, 5, 10) groups (P = .08) or between the placebo (6.5 days; 95% CI, 3, 9) and control groups (P = .89). Median time to resolution was shorter (P = .008) in the placebo compared to the treatment group (6.5 versus 10.5 days). Case fatality rates among groups (treatment, 12% versus placebo, 3% versus control, 3%) were not different (P = .36). CONCLUSIONS AND CLINICAL IMPORTANCE: Expected benefits of conferring local gut immunity by immunoglobulin supplementation in calves with diarrhea were not evident.

growth-like factor, 2 epidermal growth factor, 3 transforming growth factor-β, 4 and platelet-derived growth factor. 1 Colostral immunoglobulins provide defense in both treatment and prevention of viral and bacterial infections, whereas growth factors promote gut integrity and mucosal recovery in cattle with diarrhea 5 through differentiation of both immature and mature cells in the gastrointestinal tract. [6] [7] [8] Consequently, the benefits of feeding bovine colostrum or colostrum supplements in human patients with diarrhea have been investigated with variable outcomes. Oral supplementation with a bovine colostrum supplement in patients with human immunodeficiency virus (HIV) infection-associated diarrhea results in a dramatic decrease in stool evacuations per day, decrease in self-estimated fatigue, and an increase in body weight. 9 In contrast, supplementation with bovine colostrum in human patients with short bowel syndrome results in an increase in diarrhea with no improvement in intestinal absorption. 10 Diarrhea is the most common disease condition in preweaned dairy calves in the United States, accounting for 56.4% of deaths. 11 In nonsick calves, oral supplementation with immunoglobulin G (IgG) from 2 to 14 days of age reduced frequency of occurrence of diarrhea, and improved daily weight gain. 12 Oral administration of colostrum or immunoglobulin supplements might provide local immunity in the gastrointestinal tract of calves, thereby reducing frequency and/or preventing the occurrence of diarrhea.

Recent legislation, including the Federal Veterinary Feed Directive in 2017 13 and the California Senate Bill-27 in 2018, 14 was enacted into law and recommended judicious use of antibiotics in food producing animals.

Thus, nonantibiotic alternatives for managing diarrhea in calves are an important management strategy in promoting judicious use of antibiotics, thereby minimizing antibiotic resistance. Given the reported benefits of bovine colostrum or immunoglobulin supplements in human and bovine studies and their potential use as nonantibiotic alternatives, investigations on their use for management of calf diarrhea are warranted. We hypothesized that oral supplementation with immunoglobulins in neonatal dairy calves with diarrhea will reduce treatment events, time to resolution of diarrhea, and mortality rates compared with placebo and control calves. The objectives of this study were to determine the effect of oral immunoglobulin supplementation for 14 days on the number of treatment events, time to resolution of diarrhea, and mortality rates in preweaned dairy calves with diarrhea.

A randomized clinical trial was performed on a single 1800-cow milking Jersey dairy farm. The primary outcome of interest was resolution of diarrhea. Sample size was calculated based on a 5% significance level, power of 80%, assumption that control (CONT) group calves (no oral immunoglobulin supplementation) were 2 times or more likely to be treated compared to treatment (TRXT) group calves (oral immunoglobulin supplementation), and a difference of at least 2 treatment days between the CONT (5 days) and TRXT group calves (3 days), an SD of 2 treatment days, and a 20% dropout rate because of loss of follow-up or incomplete records. The total sample size required was 102 calves (34 calves per group).

Adult cows on the farm of study were vaccinated annually with a modified live respiratory disease vaccine containing infectious bovine rhinotracheitis, bovine viral diarrhea, parainfluenza-3, and bovine respiratory syncytial viruses. Additionally, the cows were vaccinated with a multivalent vaccine containing Escherichia coli, rotavirus, and coronavirus during the dry cow period. Newborn calves were separated from the dam within 3 hours after parturition, fed 4 L of pooled pasteurized colostrum (2 feedings of 2 L) within 12 hours, and then housed in individual hutches. Calves were then fed 2 L of pasteurized milk 3 times daily at 6 am, 12 pm, and 8 pm. Calves were fed a commercial calf concentrate recommended for preweaned Jersey calves, containing no antibiotics from 3 days of age to weaning (70 days).

Neonatal heifer calves diagnosed with diarrhea by the authors based on a fecal consistency scoring system 15 and deemed nonseptic based on a septic scoring system 16 were randomly assigned using a random generator number into 1 of the following calf groups: TRXT, placebo (PLCB), or CONT. The CONT group calves received no supplements in the milk, and the final total solids content of the milk after preparation ranged from 12 to 14% based on a digital refractometer reading (Palm Abbe Table 1 . The PLCB group calves were supplemented with 182 g of a supplement powder of similar nutritional value as the TRXT group calves, but without the IgG (Lifeline Intervene, APC Inc, Boone, Iowa), mixed thoroughly with milk, twice daily for 14 days. Nutrients of the supplement fed to the PLCB group calves are summarized in Table 1 .

Thorough mixture of the supplement with milk was achieved by using an electric kitchen whisk. To avoid delaying of the feeding process of calves by the farm personnel, total solid concentrations were not measured after mixing the supplements with milk. To ensure accurate addition of the supplements and record keeping, nipple bottles for feeding enrolled calves were color coded with blue, black, and red colors using indelible markers representing the 3 groups. The colors on the nipple bottles were then matched with colors placed on individual calf hutches. The authors performed addition of supplements to the milk, mixing, and feeding of all enrolled calves. The farm personnel and the author (M.C.) who performed data analysis were blinded to the group assignments. Supplement addition to the milk for the TRXT and PLCB group calves were performed at the 6 am and 12 pm feedings. All 102 calves were enrolled within 5 days of commencement of the study. The study was performed from June 2018 to July 2018 and was approved by the Institutional Animal Care and Use Committee (IACUC #19628).

Fecal consistency of calves was monitored twice daily by the authors based on a fecal scoring system. 15 The volume of milk consumed by each calf at the 2 feeding times was estimated and recorded by the authors. Time (days) at which the fecal score was deemed normal based on the fecal scoring system was recorded. Decision to treat calves with diarrhea and the choice of medical treatments were performed by trained farm personnel, based on the farm's standard operating procedures designed by the attending licensed farm veterinarian. Records of all medical treatments including type of treatments, duration of treatment, and deaths were available to the authors through the electronic farm record system. The attending licensed farm veterinarian performed field necropsies on calves that died.

The farm routinely collected blood from all calves at 2-7 days of age for evaluation of passive immunity status by serum total solids determination using a hand-held optical refractometer (Master automatic compensation clinical refractometer, Atago Inc, Bellevue, Washington). The authors had access to the serum samples for further analysis. When samples were not available, missing, or were severely hemolyzed, the authors collected blood from calves (2-7 days of age) at enrollment, and harvested serum from blood samples after centrifugation at 288g for 5 minutes at 4 C. Serum samples were then stored at −20 C until IgG determination by single radial immunodiffusion (RID). Single RID was performed using a commercially available kit with a serum IgG determination range of 180-2803 mg/dL, based on the manufacturer's recommendations (Bovine IgG test kit, Triple-J Farms, Bellingham, Washington). Serum samples with IgG concentrations >2803 mg/dL were diluted 1:2 with phosphate buffered solution, and reinoculated into the RID plate wells. Serum IgG concentrations <1000 mg/dL were indicative of failure of transfer of passive immunity. 17 

A commercially available statistical software application was used for all analyses (JMP Pro14, SAS Institute, Cary, North Carolina). Normality of the data was checked using the Shapiro-Wilk test. Mean ± SD were reported for normally distributed data, whereas median and range were reported for non-normally distributed data. Descriptive statistics for age at enrollment, serum IgG concentrations, and daily milk intake were calculated. Differences in age, serum IgG concentrations, daily milk intake, and fecal scores at enrollment for the 3 groups were compared using a 1-way analysis of variance, Dunnett's, or

Kruskal-Wallis tests depending on whether data were normally distributed or not. Differences in proportions of calves with failure of transfer of passive immunity, calves medically treated for diarrhea, and mortality rates among the 3 groups were compared using the χ 2 test or Fisher's exact test when a cell had <5 counts in a 2 × 2 frequency table. In cases where a cell had zero counts in a 2 × 2 frequency table, 0.5 was added to all cells. A conditional follow-up logistic regression was only considered if differences in the proportions with failure of transfer of passive immunity, calves medically treated for diarrhea, and mortality rates among the groups were significant.

Time to resolution of diarrhea with 95% confidence intervals (CIs) as a function of group assignment was determined using survival analysis by construction of Kaplan-Meier plots. For the survival analysis, the entry point into the study was at enrollment, and the exit point was at 14 days after enrollment. The specified outcome of interest was resolution of diarrhea based on fecal scoring. At the exit time point, calves that did not have the outcome of interest (resolution of diarrhea) were censored. Differences in time to resolution of diarrhea among the 3 survival plots were compared using the Sidak test. The effect of age at enrollment, serum IgG concentrations, fecal score at enrollment, medical treatments, and daily milk intake as explanatory variables for time to resolution of diarrhea was determined using the Cox proportional hazard model, and subsequent determination of risk ratios. Risk ratios <1 or >1 with a corresponding P < .05 were considered significant. In all analyses P <.05 was significant.

All data points were non-normally distributed, thus nonparametric tests were used for data analysis. Median (range) age at enrollment for all calves was 9 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) days. Median (range) age at enrollment for the TRXT, PLCB, and CONT group calves were 9 (1-19), 9 (1-19) , and 9 (1-17) days, respectively. There were no differences in the calf age at enrollment between TRXT and CONT, PLCB and CONT, or TRXT and PLCB (all P > .99). Median (range) fecal score at enrolment for all calves was 2 (1-3).

Median (range) fecal score at enrollment for the TRXT, PLCB, and Six calves died during the study period. Of the calves that died, 4 (12%) were from the TRXT, 1 (3%) from the PLCB, and 1 (3%) from the CONT groups (P = .36). The tentative causes of death based on field necropsies in the 6 calves that died were severe dehydration, sepsis, or a combination of dehydration and sepsis.

Median (95% CI) time to resolution of diarrhea for the TRXT, PLCB, and CONT groups were 10.5 (7, 13), 6.5 (3, 9) , and 8 (5, 10) days, respectively. Time to resolution of diarrhea was shorter (P = .008) in the PLCB group than in the TRXT group. There was no difference in the time to resolution of diarrhea between the PLCB and CONT (P = .89) or TRXT and CONT groups (P = .08). Kaplan-Meier curves for the 3 groups are depicted in Figure 1 . Age at enrollment (P = .36), serum IgG concentration (P = .49), fecal score at enrollment (P = .11), daily milk consumption (P = .23), F I G U R E 1 Kaplan-Meier curves depicting time to resolution of diarrhea in 3 groups of Jersey calves (N = 102). Median (95% confidence interval) time to resolution of diarrhea for the TRXT, PLCB, and CONT groups were 10.5 (7, 13), 6.5 (3, 9) , and 8.0 (5, 10) days, respectively. CONT, control; PLCB, placebo; TRXT, treatment Several reasons might explain the lack of effect on diarrhea after addition of immunoglobulins in milk in our study. We added 20 g of immunoglobulins per feeding (40 g per day) based on a previous study in calves which reported a reduction in frequency of occurrence of diarrheal disease in nonsick calves when 10 g of IgG was added twice daily to milk replacer. 12 Considering that calves in our study had diarrhea, we estimated that supplementing with twice as much immunoglobulins compared to previous studies 12 Calves in the TRXT group were supplemented with immunoglobulin derived from bovine serum. Serum derived immunoglobulin supplements contain higher IgG 2 concentrations than IgG 1 because bovine serum contains higher IgG 2 concentrations. 35 In contrast, bovine colostrum-derived immunoglobulin supplements contain higher IgG 1 concentrations than IgG 2 because IgG 1 is selectively secreted from the cow's circulation into colostrum. 36 Although IgG 1 is considered the principal immunoglobulin for passive immunization (requiring absorption from the gut), our study assessed local immunity by the immunoglobulins. Although previous reviews indicated that only IgG 1 activates complement, 35 other studies indicated that both bovine IgG 1 and IgG 2 activate complement and mediate phagocytosis. 36 Potentially, response of calves with diarrhea to supplementation with bovine serum-derived immunoglobulin might differ from bovine colostrum-derived immunoglobulin.

The morbidity because of diarrhea in our study was relatively high.

We performed the study during the summer season when ambient temperatures ranged from 32 to 42 C (humidity <60%), and the farm experiences higher incidence of diarrhea during this season. Although all the calves experienced the same weather conditions, higher ambient temperature might affect the combination of viral, bacterial, and protozoal pathogens present in the environment. We performed our study during this season to ensure that our study results and recommendations will be relevant to the period where the farm experiences the highest incidence of diarrhea.

Our study had several limitations. We did not isolate the patho- Further studies to assess effects of supplementation of immunoglobulins need to determine the effective dose (if any) by feeding calves incremental doses of immunoglobulin supplements. Additionally, it will be desirable for calves to be blocked by failure of immunity status to assess time to resolution of diarrhea, determine the specific pathogens causing the diarrhea, and determine fecal IgG excretion by labeling the oral IgG with markers such as biotin.

Results of our study indicate that supplementation of 20 g of immunoglobulins twice daily in milk did not reduce the time to resolution of diarrhea, treatment events, or mortality rate in dairy calves with diarrhea. The hypothesized benefit of conferring local gastrointestinal immunity by addition of immunoglobulins in milk was not evident. We suggest further studies to determine the effective dose of immunoglobulins that might confer local gut immunity in dairy calves with diarrhea.

Technological options for the production of health promoting proteins and peptides derived from milk and colostrum

Determination of transforming growth factorbeta 1 (TGF-beta 1) and insulin-like growth factor (IGF-1) in bovine colostrum samples

Colostrum and milk-derived peptide growth factors for the treatment of gastrointestinal disorders

Determination of transforming growth factor-beta 2 (TGFbeta 2) in bovine colostrum samples

Growth factors and antimicrobial factors of bovine colostrums

Treatment with IGF-I peptides improves function of the remnant gut following small bowel resection in rats

Effect of IGF-rich colostrum on bowel adaptation in neonatal piglets with short bowel syndrome

A pilot study of the use of epidermal growth factor in pediatric short bowel syndrome

ColoPlus, a new product based on bovine colostrum, alleviates HIV-associated diarrhea

Randomised controlled trial of colostrum to improve intestinal function in patients with short bowel syndrome

Department of Agriculture and Plant Health Inspection Service, Veterinary Services, Health and management practices on U.S dairy operations

Evaluation of the effects of oral colostrum supplementation during the first fourteen days on the health and performance of preweaned calves

Veterinary Feed Directive (VFD)

Livestock: use of antimicrobial drugs

Disease management of dairy calves and heifers

Use of a clinical sepsis score for predicting bacteremia in neonatal dairy calves on a calf rearing farm

The importance of colostrum to the health of the neonatal calf

Use of protein concentration to predict mortality in mixed-source dairy replacement heifers

Treatment of diarrhoea in human immunodeficiency virus-infected patients with immunoglobulins from bovine colostrum

A preparation from bovine colostrum in the treatment of HIV-positive patients with chronic diarrhea

Treatment of severe diarrhea caused by Cryptosporidium parvum with oral bovine immunoglobulin concentrate in patients with AIDS

Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients

Enteric lesions and diarrhea in gnotobiotic calves monoinfected with Cryptosporidium species

Pathophysiology of neonatal calf diarrhea

Rotaviral and coronaviral diarrhea

Pathogenesis of intestinal and systemic rotavirus infection

Pathophysiologic changes due to coronavirus-induced diarrhea in the calf

Scanning electron microscopic characterization of bovine coronavirus plaques in HRT cells

Occurrence and characteristics of enterotoxigenic Escherichia coli isolated from calves with diarrhea

Enterotoxigenic Escherichia coli infections in newborn calves: a review

Some infectious causes of diarrhea in young farm animals

Technical report: results of immunological tests on fecal extracts are likely to be extremely misleading

A randomized clinical trial evaluating metabolism of colostral and plasma derived immunoglobulin G in Jersey bull calves

Measurement of immunoglobulin concentrations in the feces of healthy dogs

Bovine immunoglobulins: a review

Functional properties of bovine IgG1 and IgG2: interaction with complement, macrophages, neutrophils and skin

Neonatal diarrhea

Hyperkalemia in neonatal diarrheic calves depends on the degree of dehydration and the cause of the metabolic acidosis but does not require the presence of acidemia

Risk factors for the development of hypokalemia in neonatal diarrheic calves

Water and electrolyte losses in neonatal calves with acute diarrhea. A complete balance study

Electrocardiographic findings in 130 hospitalized neonatal calves with diarrhea and associated potassium balance disorders

Randomized controlled clinical trial on the effect of oral immunoglobulin supplementation on neonatal dairy calves with diarrhea

The authors thank Brett Barlass and the calf caretaking personnel at the farm of study for their assistance.

Authors declare no conflict of interest.

Authors declare no off-label use of antimicrobials.

The study was approved by the University of California Davis IACUC #19628.

Authors declare human ethics approval was not needed for this study.

https://orcid.org/0000-0001-6841-2448